-
Stocks to Watch: Moving Average Indicators
Monday, June 20, 2011 - 3:31am | 626The “Golden Cross” is a major bullish technical indicator. It occurs when a stock's 50-day simple moving average crosses above its 200-day simple moving average. The “Golden Cross,” like most technical indicators, should never be used alone, but is a significant event to consider when evaluating a...
-
Breakout Stocks to Watch This Week and 1 Speculative Biotech
Sunday, June 19, 2011 - 10:53pm | 2824Click here for a FREE Trading Course Now you can follow me on Stocktwits and Twitter! Each week I publish stocks to watch for the upcoming week as potential momentum trades or longer-term investments. The stocks below all have a 50k minimum average daily share volume and traded at a 52-week high...
-
8 Potential Biotech Acquisition Candidates
Sunday, June 19, 2011 - 2:54pm | 127Here are 8 promising biotechs priced for a buyout if their products can deliver: BioMarin Pharmaceutical Inc. (BMRN): It's not the most profitable company, but BioMarin Pharmaceuticals certainly has some promising products in its portfolio. The company first achieved profitability in 2008, and its...
-
T. Boone Pickens' 4 Newest Energy Stock Picks
Sunday, June 19, 2011 - 2:52pm | 127Here are 8 promising biotechs priced for a buyout if their products can deliver: BioMarin Pharmaceutical Inc. (BMRN): It's not the most profitable company, but BioMarin Pharmaceuticals certainly has some promising products in its portfolio. The company first achieved profitability in 2008, and its...
-
Pandora: The Latest Sign of Tech Bubble 2.0
Sunday, June 19, 2011 - 2:50pm | 127Here are 8 promising biotechs priced for a buyout if their products can deliver: BioMarin Pharmaceutical Inc. (BMRN): It's not the most profitable company, but BioMarin Pharmaceuticals certainly has some promising products in its portfolio. The company first achieved profitability in 2008, and its...
-
10 Dividend Kings Every Smart Investor Should Own
Sunday, June 19, 2011 - 2:48pm | 127Here are 8 promising biotechs priced for a buyout if their products can deliver: BioMarin Pharmaceutical Inc. (BMRN): It's not the most profitable company, but BioMarin Pharmaceuticals certainly has some promising products in its portfolio. The company first achieved profitability in 2008, and its...
-
Regeneron Announces EYLEA Receives Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory Committee
Friday, June 17, 2011 - 2:05pm | 74Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration has voted unanimously to recommend that the FDA approve EYLEA™, also known as VEGF Trap-Eye, for the treatment of the neovascular...
-
Seattle Genetics Announces Promotion of Eric Dobmeier to COO
Friday, June 17, 2011 - 12:30pm | 50Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Eric L. Dobmeier has been promoted to the newly created position of Chief Operating Officer. Mr. Dobmeier has been with Seattle Genetics for more than nine years, serving most recently as Chief Business Officer.
-
Celgene Announces Phase II Data Evaluating Clinical Benefit of REVLIMID Plus Rituximab Presented at International Conference on Malignant Lymphoma
Friday, June 17, 2011 - 12:01pm | 102Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's...
-
Options Brief: PharmAthene, Inc.
Friday, June 17, 2011 - 11:08am | 71Shares of PharmAthene, Inc. (AMEX: PIP) are lower on the session by 3.62%, trading at $2.66. Overall call volume is now running at 7.41x the daily average, with 3% of all calls traded being purchases on the offer. 4,152 contracts have traded on the session so far. PharmAthene, Inc. is a...
-
Cleveland BioLabs to Raise $23.5M in Registered Direct Offering
Friday, June 17, 2011 - 9:01am | 206Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced it has received commitments from certain institutional and accredited investors to purchase an aggregate of $23.5 million of the Company's securities in a registered direct offering. The Company entered into definitive purchase agreements...
-
Regeneron Halted Ahead Of FDA
Friday, June 17, 2011 - 9:01am | 95Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) are halted going into a meeting with the U.S. Food and Drug Administration and the Dermatologic and Ophthalmic Drugs Advisory Committee to discuss Regeneron's license application for treating certain kinds of vision loss. The drug, EYLEA or...
-
Pharmacyclics Announces Results of Registered Direct Offering of 6.5M Shares
Friday, June 17, 2011 - 8:34am | 92Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has entered into stock purchase agreements with various institutional investors and its CEO for the sale of 6,448,829 shares of its common stock in a registered direct offering at $8.85 per share, the closing price on June 16, 2011....
-
Benzinga's Top Upgrades
Friday, June 17, 2011 - 8:25am | 135JP Morgan upgraded Broadridge Financial Solutions Inc (NYSE: BR) from “neutral” to “overweight.” BR's shares closed at $22.08 yesterday. Broadridge's trailing-twelve-month ROE is 22.29%. Analysts at Sterne Agee upgraded DryShips Inc (NASDAQ: DRYS) from “neutral” to “buy.” DRYS' shares closed at $3...
-
Piper Jaffray Updates On ISIS Following Shareholders Meeting
Friday, June 17, 2011 - 8:11am | 151Piper Jaffray is maintaining its Neutral rating and its $10 price target on Isis Pharmaceuticals (NASDAQ: ISIS) following the company's annual meeting with shareholders. In the report, Piper Jaffray states, “ISIS hosted a webcast presentation of its annual Shareholders Meeting highlighting the...